Downregulation of ERp57 expression is associated with poor prognosis in early-stage cervical cancer

Biomarkers

Volumn 18, Issue 7, 2013, Pages 573-579

  Chung, Hyunsoo ^a   Cho, Hanbyoul ^b   Perry, Candice ^a   Song, Jaekyung ^b   Ylaya, Kris ^a   Lee, Heejeong ^c   Kim, Jae Hoon ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Cervical cancer; ERp57; Immunohistochemistry; Survival; Tissue microarray

Indexed keywords

CELL PROTEIN; CISPLATIN; MESSENGER RNA; PROTEIN ERP57; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; CELLULAR DISTRIBUTION; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE INTERVAL; DOWN REGULATION; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PELVIS LYMPH NODE; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; TUMOR VOLUME; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; PROTEIN DISULFIDE-ISOMERASES; PROTEIN TRANSPORT; TISSUE ARRAY ANALYSIS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84888871962     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.827742     Document Type: Article

References (17)

1. Atkins D, Ferrone S, Schmahl GE, et al. (2004). Down-regulation of HLA class I antigen processing molecules: An immune escape mechanism of renal cell carcinoma? J Urol 171:885-9
2. Chun M. (2009). Time for global efforts with clinical trials for advanced cervical cancer patients. J Gynecol Oncol 20:201-2.
3. Garbi N, Tanaka S, Momburg F, Hammerling GJ. (2006). Impaired assembly of the major histocompatibility complex class I peptideloading complex in mice deficient in the oxidoreductase ERp57. Nat Immunol 7:93-102.
4. Garland SM, Bhatla N, Ngan HY. (2012). Cervical cancer burden and prevention strategies: Asia Oceania perspective. Cancer Epidemiol Biomarkers Prev 21:1414-22.
5. Hasim A, Abudula M, Aimiduo R, et al. (2012). Post-transcriptional and epigenetic regulation of Antigen Processing Machinery (APM) components and HLA-I in cervical cancers from Uighur women. PLoS One 7:e44952.
6. Igney FH, Krammer PH. (2002). Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 71:907-20.
7. Kirkegaard T, Edwards J, Tovey S, et al. (2006). Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48:787-94
8. Leys CM, Nomura S, LaFleur BJ, et al. (2007). Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery 141:41-50.
9. Lindquist JA, Hammerling GJ, Trowsdale J. (2001). ER60/ERp57 forms disulfide-bonded intermediates with MHC class I heavy chain. FASEB J 15:1448-50.
10. Lindquist JA, Jensen ON, Mann M, Hammerling GJ. (1998). ER-60, a chaperone with thiol-dependent reductase activity involved in MHC class I assembly. EMBO J 17:2186-95.
11. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-8.
12. Mehta AM, Jordanova ES, Kenter GG, et al. (2008). Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57:197-206.
13. Moody CA, Laimins LA. (2010). Human papillomavirus oncoproteins: Pathways to transformation. Nat Rev Cancer 10:550-60.
14. Noh KH, Kim BW, Song KH, et al. (2012). Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest 122: 4077-93.
15. Ogino T, Bandoh N, Hayashi T, et al. (2003). Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 9:4043-51.
16. Radcliffe CM, Diedrich G, Harvey DJ, et al. (2002). Identification of specific glycoforms of major histocompatibility complex class I heavy chains suggests that class I peptide loading is an adaptation of the quality control pathway involving calreticulin and ERp57. J Biol Chem 277:46415-23.
17. Seliger B, Wollscheid U, Momburg F, et al. (2000). Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens 56:327-36.